Entera Bio Statistics

Total Valuation

Entera Bio has a market cap or net worth of $64.66 million. The enterprise value is $55.94 million.

Market Cap	64.66M
Enterprise Value	55.94M

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024, after market close.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Entera Bio has 36.32 million shares outstanding. The number of shares has increased by 14.75% in one year.

Current Share Class	36.32M
Shares Outstanding	36.32M
Shares Change (YoY)	+14.75%
Shares Change (QoQ)	+0.97%
Owned by Insiders (%)	2.25%
Owned by Institutions (%)	3.89%
Float	25.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	7.58
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	981.33
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.41, with a Debt / Equity ratio of 0.04.

Current Ratio	7.41
Quick Ratio	7.04
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -101.84% and return on invested capital (ROIC) is -61.07%.

Return on Equity (ROE)	-101.84%
Return on Assets (ROA)	-52.34%
Return on Capital (ROIC)	-61.07%
Revenue Per Employee	$3,167
Profits Per Employee	-$474,222
Employee Count	18
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

In the past 12 months, Entera Bio has paid $29,000 in taxes.

Income Tax	29,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +190.42% in the last 52 weeks. The beta is 1.59, so Entera Bio's price volatility has been higher than the market average.

Beta (5Y)	1.59
52-Week Price Change	+190.42%
50-Day Moving Average	1.86
200-Day Moving Average	1.77
Relative Strength Index (RSI)	43.65
Average Volume (20 Days)	20,983

Short Selling Information

Short Interest	40,395
Short Previous Month	47,169
Short % of Shares Out	0.11%
Short % of Float	0.16%
Short Ratio (days to cover)	1.24

Income Statement

In the last 12 months, Entera Bio had revenue of $57,000 and -$8.54 million in losses. Loss per share was -$0.26.

Revenue	57,000
Gross Profit	9,000
Operating Income	-8.58M
Pretax Income	-8.51M
Net Income	-8.54M
EBITDA	-8.53M
EBIT	-8.58M
Loss Per Share	-$0.26

Full Income Statement

Balance Sheet

The company has $9.06 million in cash and $334,000 in debt, giving a net cash position of $8.72 million or $0.24 per share.

Cash & Cash Equivalents	9.06M
Total Debt	334,000
Net Cash	8.72M
Net Cash Per Share	$0.24
Equity (Book Value)	8.53M
Book Value Per Share	0.23
Working Capital	8.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$7.34 million and capital expenditures -$5,000, giving a free cash flow of -$7.34 million.

Operating Cash Flow	-7.34M
Capital Expenditures	-5,000
Free Cash Flow	-7.34M
FCF Per Share	-$0.20

Full Cash Flow Statement

Margins

Gross Margin	15.79%
Operating Margin	-15,045.61%
Pretax Margin	-14,924.56%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-12,884.21%

Dividends & Yields

Entera Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.75%
Shareholder Yield	-14.75%
Earnings Yield	-13.20%
FCF Yield	-11.36%

Analyst Forecast

The average price target for Entera Bio is $10.00, which is 461.80% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	461.80%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Entera Bio has an Altman Z-Score of -1.38 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.38
Piotroski F-Score	3